ALX Oncology Holdings Inc. (ALXO)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
ALXO trades thinly or has a short history, so some panels below have little to show.
Follow ALXO in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ALXO and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ALXO at a glance
Key statistics
$171.46M
Market capitalization
- Previous close
- $1.24
- Open
- $1.25
- Day range
- $1.15 – $1.30
- Volume
- 934.5K
- Average volume (30 sessions)
- 1.47M
- Shares outstanding
- 138.28M
- Earnings per share
- $(0.58)
- Price / book
- 1.3
- Beta (1 year, vs SPY)
- 0.64
Where the price sits in its year
52-week range
16% of the range
- Below the 52-week high
- -56.8%
- Above the 52-week low
- +33.5%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $1.20-3.8%
- 50-day average
- $1.63-29.4%
- 200-day average
- $1.83-37.1%
Between the conventional 30 and 70 bands.
+28.5%
1 week
-28.1%
1 month
-43.1%
3 months
+1.8%
Year to date
-30.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ALXO
ALXO on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ALXO.
See the plans →
Every planScreen names like ALXO
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ALXO
Put ALXO on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ALXO
See whether there is an open premium alert on ALXO, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ALXO headlines
- ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc. · Feb 27, 2026
- ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc. · Jan 8, 2026
- ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
GlobeNewswire Inc. · Dec 7, 2025
- ALX Oncology to Present at Upcoming Investor Conferences
GlobeNewswire Inc. · Nov 18, 2025
- ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
GlobeNewswire Inc. · May 13, 2025
- ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
GlobeNewswire Inc. · Dec 18, 2024
- ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
GlobeNewswire Inc. · Nov 1, 2024
SEC Form 4, most recent first
Insider filings
Lettmann Jason
−2.2K
CHIEF EXECUTIVE OFFICER, Director · Open-market sale
$4.30K · Aug 17, 2026
Wong Shelly
−573
SVP, FINANCE AND CAO · Open-market sale
$1.11K · Aug 17, 2026
Wong Shelly
−1.4K
SVP, FINANCE AND CAO · Open-market sale
$2.86K · Jul 1, 2026
Knight Jeff E.
+800.0K
Chief Dev & Operating Officer · Grant or award
· Apr 16, 2026
Klencke Barbara
+100.0K
Chief Medical Officer · Grant or award
· Apr 16, 2026
Pinto Shelly
−903
SVP, FINANCE AND CAO · Open-market sale
$1.96K · Mar 19, 2026
Lettmann Jason
−12.3K
CHIEF EXECUTIVE OFFICER, Director · Open-market sale
$26.71K · Mar 19, 2026
Klencke Barbara
+700.0K
Chief Medical Officer · Grant or award
· Mar 3, 2026
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Employees
- 48
- Listed since
- Jul 17, 2020
- Website
- alxoncology.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.